First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
暂无分享，去创建一个
R. Wenham | G. Wilding | S. Kaye | C. Toniatti | J. D. de Bono | S. Sandhu | W. Schelman | L. R. Molife | M. Stroh | V. Moreno García | C. Carpenter | L. Sun | N. Kreischer | L. Sun